miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
26 Apr 2020
Historique:
received: 16 12 2019
accepted: 14 04 2020
entrez: 28 4 2020
pubmed: 28 4 2020
medline: 22 1 2021
Statut: epublish

Résumé

Increasing evidence indicates that epithelial-mesenchymal transition (EMT) can be regulated by microRNAs (miRNAs). miR-615-3p was shown to be involved in tumor development. However, the role of miR-615-3p in the metastasis of breast cancer remains largely unknown. The expression of miR-615-3p in breast cancer cells and tissues was assessed by qRT-PCR and situ hybridization assays. Effects of miR-615-3p on tumor metastasis were evaluated with experiments in vitro and mouse model. EMT markers were detected by western blot and immunofluorescence assays. Molecular mechanism of miR-615-3p in the regulation of breast cancer cell metastasis was analyzed by Western Blot, Co-immunoprecipitation, and Luciferase assay. In the present study, we found that miR-615-3p was significantly elevated in breast cancer cells and tissues, especially in those with metastasis. In breast cancer cell lines, stable overexpression of miR-615-3p was sufficient to promote cell motility in vitro, and pulmonary metastasis in vivo, accompanied by the reduced expression of epithelial markers and the increased levels of mesenchymal markers. Further studies revealed that the reintroduction of miR-615-3p increased the downstream signaling of TGF-β, the type I receptor (TGFBRI) by targeting the 3'-untranslated regions (3'-UTR) of PICK1. PICK1 inhibits the binding of DICER1 to Smad2/3 and the processing of pre-miR-615-3p to mature miR-615-3p in breast cancer cells, thus exerting a negative feedback loop. Our data highlight an important role of miR-615-3p in the molecular etiology of breast cancer, and implicate the potential application of miR-615-3p in cancer therapy.

Sections du résumé

BACKGROUND BACKGROUND
Increasing evidence indicates that epithelial-mesenchymal transition (EMT) can be regulated by microRNAs (miRNAs). miR-615-3p was shown to be involved in tumor development. However, the role of miR-615-3p in the metastasis of breast cancer remains largely unknown.
METHODS METHODS
The expression of miR-615-3p in breast cancer cells and tissues was assessed by qRT-PCR and situ hybridization assays. Effects of miR-615-3p on tumor metastasis were evaluated with experiments in vitro and mouse model. EMT markers were detected by western blot and immunofluorescence assays. Molecular mechanism of miR-615-3p in the regulation of breast cancer cell metastasis was analyzed by Western Blot, Co-immunoprecipitation, and Luciferase assay.
RESULTS RESULTS
In the present study, we found that miR-615-3p was significantly elevated in breast cancer cells and tissues, especially in those with metastasis. In breast cancer cell lines, stable overexpression of miR-615-3p was sufficient to promote cell motility in vitro, and pulmonary metastasis in vivo, accompanied by the reduced expression of epithelial markers and the increased levels of mesenchymal markers. Further studies revealed that the reintroduction of miR-615-3p increased the downstream signaling of TGF-β, the type I receptor (TGFBRI) by targeting the 3'-untranslated regions (3'-UTR) of PICK1. PICK1 inhibits the binding of DICER1 to Smad2/3 and the processing of pre-miR-615-3p to mature miR-615-3p in breast cancer cells, thus exerting a negative feedback loop.
CONCLUSIONS CONCLUSIONS
Our data highlight an important role of miR-615-3p in the molecular etiology of breast cancer, and implicate the potential application of miR-615-3p in cancer therapy.

Identifiants

pubmed: 32336285
doi: 10.1186/s13046-020-01571-5
pii: 10.1186/s13046-020-01571-5
pmc: PMC7183699
doi:

Substances chimiques

Carrier Proteins 0
MIRN615 microRNA, human 0
MicroRNAs 0
Nuclear Proteins 0
PICk1 protein, human 0
Receptor, Transforming Growth Factor-beta Type I EC 2.7.11.30
TGFBR1 protein, human EC 2.7.11.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

71

Références

Breast Cancer Res. 2017 Oct 5;19(1):111
pubmed: 28982386
Oncotarget. 2017 Aug 3;8(39):66226-66236
pubmed: 29029506
J Exp Clin Cancer Res. 2019 Jan 15;38(1):20
pubmed: 30646925
Int J Mol Sci. 2017 Nov 25;18(12):
pubmed: 29186838
Oncogene. 2017 Feb 23;36(8):1157-1166
pubmed: 27524420
Cell Mol Life Sci. 2019 Feb;76(3):441-451
pubmed: 30374521
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Cancer Res. 2008 Sep 15;68(18):7304-12
pubmed: 18794117
Immunity. 2015 Jul 21;43(1):65-79
pubmed: 26141582
Nat Med. 2012 Feb 19;18(3):429-35
pubmed: 22344298
Clin Cancer Res. 2017 Jun 15;23(12):3120-3128
pubmed: 27965308
Cell Physiol Biochem. 2018;45(2):692-705
pubmed: 29414807
Nat Rev Drug Discov. 2004 Dec;3(12):1047-56
pubmed: 15573103
Cell. 2016 Feb 25;164(5):1015-30
pubmed: 26898331
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Mol Cancer. 2019 Mar 13;18(1):40
pubmed: 30866952
Mol Biol Cell. 2015 Dec 15;26(25):4552-61
pubmed: 26466675
Nature. 2007 Oct 11;449(7163):682-8
pubmed: 17898713
Cancer Discov. 2013 Aug;3(8):846-8
pubmed: 23928773
Oncogene. 2008 Dec 11;27(58):7235-47
pubmed: 18794808
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Oncogene. 2019 Mar;38(12):2076-2091
pubmed: 30442980
Cell Biol Toxicol. 2007 Mar;23(2):113-28
pubmed: 17096210
Sci Signal. 2017 Jun 13;10(483):
pubmed: 28611183
Science. 2003 Sep 5;301(5638):1394-7
pubmed: 12958365
Cell Res. 2012 Oct;22(10):1467-78
pubmed: 22710801
Br J Cancer. 2017 Aug 22;117(5):685-694
pubmed: 28697177
Sci Rep. 2015 Jul 07;5:11853
pubmed: 26149967
Oncotarget. 2016 Sep 6;7(36):58595-58605
pubmed: 27517632
Oncogene. 2014 May 1;33(18):2307-16
pubmed: 23686305
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biochim Biophys Acta. 2015 Jul;1852(7):1520-30
pubmed: 25887159
EMBO Rep. 2014 May;15(5):548-56
pubmed: 24723684
Cancer Sci. 2010 Jun;101(6):1536-42
pubmed: 20384629
Int J Oncol. 2015 Oct;47(4):1351-60
pubmed: 26252200
Nat Commun. 2018 Jan 8;9(1):100
pubmed: 29311615
Cancer Lett. 2019 Sep 10;459:168-175
pubmed: 31163194
PLoS Genet. 2014 Feb 27;10(2):e1004188
pubmed: 24586208
J Cell Commun Signal. 2014 Mar;8(1):39-58
pubmed: 24338442

Auteurs

Bo Lei (B)

Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150086, China.

Dandan Wang (D)

Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China.

Ming Zhang (M)

Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150086, China.

Yuwei Deng (Y)

Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China.

Huijie Jiang (H)

Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. jianghuijie@hrbmu.edu.cn.

Yiwen Li (Y)

Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. zlylyw@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH